Stock Analysis on Net

Abiomed Inc. (NASDAQ:ABMD)

This company has been moved to the archive! The financial data has not been updated since November 3, 2022.

Price to FCFE (P/FCFE)

Microsoft Excel

Free Cash Flow to Equity (FCFE)

Abiomed Inc., FCFE calculation

US$ in thousands

Microsoft Excel
12 months ended: Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
Net income 136,505 225,525 203,009 259,016 112,170 52,116
Net noncash charges 179,081 66,439 103,886 32,022 99,303 57,667
Changes in assets and liabilities (30,196) (17,386) 8,025 (38,841) (18,927) 5,333
Net cash provided by operating activities 285,390 274,578 314,920 252,197 192,546 115,116
Purchases of property and equipment (35,763) (53,383) (44,006) (44,004) (55,863) (50,415)
Principal payments on capital lease obligation (517) (446)
Free cash flow to equity (FCFE) 249,627 221,195 270,914 208,193 136,166 64,255

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

Item Description The company
FCFE Free cash flow to equity is the cash flow available to Abiomed Inc. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Abiomed Inc. FCFE decreased from 2020 to 2021 but then increased from 2021 to 2022 not reaching 2020 level.

Price to FCFE Ratio, Current

Abiomed Inc., current P/FCFE calculation, comparison to benchmarks

Microsoft Excel
No. shares of common stock outstanding 45,091,184
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands) 249,627
FCFE per share 5.54
Current share price (P) 373.63
Valuation Ratio
P/FCFE 67.49
Benchmarks
P/FCFE, Competitors1
Abbott Laboratories 76.20
Cigna Group 10.66
CVS Health Corp. 5.45
Danaher Corp. 52.68
Elevance Health Inc. 16.37
Humana Inc. 11.53
Intuitive Surgical Inc. 188.05
Medtronic PLC 28.98
UnitedHealth Group Inc. 15.17
P/FCFE, Sector
Health Care Equipment & Services 18.30
P/FCFE, Industry
Health Care 20.76

Based on: 10-K (reporting date: 2022-03-31).

1 Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.


Price to FCFE Ratio, Historical

Abiomed Inc., historical P/FCFE calculation, comparison to benchmarks

Microsoft Excel
Mar 31, 2022 Mar 31, 2021 Mar 31, 2020 Mar 31, 2019 Mar 31, 2018 Mar 31, 2017
No. shares of common stock outstanding1 45,563,937 45,295,979 44,956,959 45,124,729 44,477,837 43,819,330
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in thousands)2 249,627 221,195 270,914 208,193 136,166 64,255
FCFE per share3 5.48 4.88 6.03 4.61 3.06 1.47
Share price1, 4 235.75 280.00 196.32 262.64 394.46 135.88
Valuation Ratio
P/FCFE5 43.03 57.34 32.58 56.93 128.85 92.66
Benchmarks
P/FCFE, Competitors6
Abbott Laboratories 26.11 24.52 38.42 53.19
Cigna Group 18.23 10.98 16.30 20.76
CVS Health Corp. 12.36 21.23 11.93 18.52
Danaher Corp. 32.04 20.75 44.62 6.88
Elevance Health Inc. 14.26 11.07 7.75 13.72
Humana Inc. 30.99 11.49 8.47 11.73
Intuitive Surgical Inc. 89.67 58.39 81.15 57.31
Medtronic PLC 19.71 38.91 23.06 26.62
UnitedHealth Group Inc. 12.57 20.11 13.93 13.90
P/FCFE, Sector
Health Care Equipment & Services 17.58 20.22 18.16 16.24
P/FCFE, Industry
Health Care 18.25 17.67 16.95 13.53

Based on: 10-K (reporting date: 2022-03-31), 10-K (reporting date: 2021-03-31), 10-K (reporting date: 2020-03-31), 10-K (reporting date: 2019-03-31), 10-K (reporting date: 2018-03-31), 10-K (reporting date: 2017-03-31).

1 Data adjusted for splits and stock dividends.

2 See details »

3 2022 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= 249,627,000 ÷ 45,563,937 = 5.48

4 Closing price as at the filing date of Abiomed Inc. Annual Report.

5 2022 Calculation
P/FCFE = Share price ÷ FCFE per share
= 235.75 ÷ 5.48 = 43.03

6 Click competitor name to see calculations.

Valuation ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. Abiomed Inc. P/FCFE ratio increased from 2020 to 2021 but then slightly decreased from 2021 to 2022 not reaching 2020 level.